S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Banking Nightmare (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Banking Nightmare (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Banking Nightmare (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Adele extends Las Vegas residency, plans concert film
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Banking Nightmare (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Biden's pick to lead FAA withdraws amid shaky Senate support
Travel disruption hits Germany on eve of transport strike
My No. 1 dividend stock for a LIFETIME of income. (Ad)
Turkmenistan votes for new, opposition-free parliament
Adele extends Las Vegas residency, plans concert film
NASDAQ:ONTX

Onconova Therapeutics - ONTX Stock Forecast, Price & News

$0.73
+0.01 (+1.39%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.69
$0.76
50-Day Range
$0.69
$1.42
52-Week Range
$0.62
$2.04
Volume
41,684 shs
Average Volume
78,108 shs
Market Capitalization
$15.26 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

ONTX stock logo

About Onconova Therapeutics (NASDAQ:ONTX) Stock

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. It focuses on discovering and developing small molecule drug candidates to treat cancer. The company was founded by Ramesh Kumar and E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA.

Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Stock News Headlines

Onconova Therapeutics (ONTX) Gets a Hold from H.C. Wainwright
The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
Q4 2022 Onconova Therapeutics Inc Earnings Call
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
ONTX.O - | Stock Price & Latest News | Reuters
See More Headlines
Receive ONTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Onconova Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ONTX Company Calendar

Last Earnings
11/11/2021
Today
3/26/2023
Next Earnings (Estimated)
5/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ONTX
Employees
14
Year Founded
N/A

Profitability

Net Income
$-18,960,000.00
Net Margins
-8,391.15%
Pretax Margin
-7,658.41%

Debt

Sales & Book Value

Annual Sales
$230,000.00
Book Value
$2.22 per share

Miscellaneous

Free Float
20,645,000
Market Cap
$15.26 million
Optionable
Not Optionable
Beta
1.84

Key Executives

  • Steven M. FruchtmanSteven M. Fruchtman
    President, Chief Executive Officer & Director
  • Mark P. Guerin
    Chief Operating & Financial Officer
  • Matthew Parris
    Vice President-Clinical Operations
  • Mark Stephen Gelder
    Chief Medical Officer
  • Adar Makovski Silverstein
    Senior Director & Head-Corporate Development













ONTX Stock - Frequently Asked Questions

Should I buy or sell Onconova Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ONTX shares.
View ONTX analyst ratings
or view top-rated stocks.

How have ONTX shares performed in 2023?

Onconova Therapeutics' stock was trading at $0.6457 at the beginning of 2023. Since then, ONTX shares have increased by 13.1% and is now trading at $0.73.
View the best growth stocks for 2023 here
.

When is Onconova Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our ONTX earnings forecast
.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics, Inc. (NASDAQ:ONTX) issued its quarterly earnings data on Thursday, November, 11th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company earned $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Onconova Therapeutics had a negative trailing twelve-month return on equity of 49.84% and a negative net margin of 8,391.15%. During the same period in the prior year, the business earned ($0.45) EPS.

When did Onconova Therapeutics' stock split?

Onconova Therapeutics's stock reverse split on the morning of Friday, May 21st 2021. The 1-15 reverse split was announced on Thursday, May 20th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 20th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Onconova Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Onconova Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), Acasti Pharma (ACST), Bionano Genomics (BNGO), Matinas BioPharma (MTNB), Outlook Therapeutics (OTLK) and Actinium Pharmaceuticals (ATNM).

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.80%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Abraham N Oler, Abraham N Oler, E Premkumar Reddy, James J Marino, Jerome Groopman, Mark Patrick Guerin and Steven M Fruchtman.
View institutional ownership trends
.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.73.

How much money does Onconova Therapeutics make?

Onconova Therapeutics (NASDAQ:ONTX) has a market capitalization of $15.26 million and generates $230,000.00 in revenue each year. The biopharmaceutical company earns $-18,960,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The official website for the company is www.onconova.com. The biopharmaceutical company can be reached via phone at (267) 759-3680, via email at ir@onconova.us, or via fax at 267-759-3681.

This page (NASDAQ:ONTX) was last updated on 3/26/2023 by MarketBeat.com Staff